Recommendations for the management of cutaneous adverse effects of inhibitors of the epidermal growth factor receptor (EGFR) are urgently needed. In this context an expert panel of German dermatologists recently proposed a 3-step management concept based on personal experience and a current literature consensus. While steps 1 and 2 addressed general and preventive measures, as well as the therapy that can be performed by the primary treating physician, here we address the management of challenging cases (step 3) that do not respond well to basic measures and should be referred to an experienced dermatologist.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1610-0387.2012.07948.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!